BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Parini R, Deodato F. Intravenous Enzyme Replacement Therapy in Mucopolysaccharidoses: Clinical Effectiveness and Limitations. Int J Mol Sci 2020;21:E2975. [PMID: 32340185 DOI: 10.3390/ijms21082975] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Ricci S, Cacialli P. Stem Cell Research Tools in Human Metabolic Disorders: An Overview. Cells 2021;10:2681. [PMID: 34685661 DOI: 10.3390/cells10102681] [Reference Citation Analysis]
2 İnci A, Okur İ, Tümer L, Biberoğlu G, Öktem M, Ezgü F. Clinical and event-based outcomes of patients with mucopolysaccharidosis VI receiving enzyme replacement therapy in Turkey: a case series. Orphanet J Rare Dis 2021;16:438. [PMID: 34666789 DOI: 10.1186/s13023-021-02060-4] [Reference Citation Analysis]
3 Kubaski F, Vairo F, Baldo G, de Oliveira Poswar F, Corte AD, Giugliani R. Therapeutic Options for Mucopolysaccharidosis II (Hunter Disease). Curr Pharm Des 2020;26:5100-9. [PMID: 33138761 DOI: 10.2174/1381612826666200724161504] [Reference Citation Analysis]
4 Hampe CS, Wesley J, Lund TC, Orchard PJ, Polgreen LE, Eisengart JB, McLoon LK, Cureoglu S, Schachern P, McIvor RS. Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement. Biomolecules 2021;11:189. [PMID: 33572941 DOI: 10.3390/biom11020189] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
5 Jafaryazdi R, Shams S, Setoodeh A, Badv RS, Ziaee V, Abbasi F, Haghi Ashtiani MT, Mozafari F, Shafeghat L. Evaluation of Patients Referred to Children's Medical Center Laboratory for Diagnosis of Mucopolysaccharidoses: Eight Years' Experience from Iran. Journal of Child Science 2021;11:e299-305. [DOI: 10.1055/s-0041-1740059] [Reference Citation Analysis]
6 McBride KL, Flanigan KM. Update in the Mucopolysaccharidoses. Semin Pediatr Neurol 2021;37:100874. [PMID: 33892850 DOI: 10.1016/j.spen.2021.100874] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Zerjav Tansek M, Kodric J, Klemencic S, Boelens JJ, van Hasselt PM, Drole Torkar A, Doric M, Koren A, Avcin S, Battelino T, Groselj U. Therapy-type related long-term outcomes in mucopolysaccaridosis type II (Hunter syndrome) - Case series. Mol Genet Metab Rep 2021;28:100779. [PMID: 34258227 DOI: 10.1016/j.ymgmr.2021.100779] [Reference Citation Analysis]
8 Kowalski T, Donoghue S, de Jong G, Mack HG. Novel chorioretinal findings in two siblings with mucopolysaccharidosis type VI. Ophthalmic Genet 2022;:1-6. [PMID: 35658818 DOI: 10.1080/13816810.2022.2083184] [Reference Citation Analysis]
9 Bhalla A, Ravi R, Fang M, Arguello A, Davis SS, Chiu CL, Blumenfeld JR, Nguyen HN, Earr TK, Wang J, Astarita G, Zhu Y, Fiore D, Scearce-Levie K, Diaz D, Cahan H, Troyer MD, Harris JM, Escolar ML. Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients. Int J Mol Sci 2020;21:E5188. [PMID: 32707880 DOI: 10.3390/ijms21155188] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
10 Tylki-Szymańska A, Almássy Z, Christophidou-Anastasiadou V, Avdjieva-Tzavella D, Barisic I, Cerkauskiene R, Cuturilo G, Djiordjevic M, Gucev Z, Hlavata A, Kieć-Wilk B, Magner M, Pecin I, Plaiasu V, Samardzic M, Zafeiriou D, Zaganas I, Lampe C. The landscape of Mucopolysaccharidosis in Southern and Eastern European countries: a survey from 19 specialistic centers. Orphanet J Rare Dis 2022;17:136. [PMID: 35331284 DOI: 10.1186/s13023-022-02285-x] [Reference Citation Analysis]
11 Rossini L, Durante C, Marzollo A, Biffi A. New Indications for Hematopoietic Stem Cell Gene Therapy in Lysosomal Storage Disorders. Front Oncol 2022;12:885639. [DOI: 10.3389/fonc.2022.885639] [Reference Citation Analysis]
12 Wang J, Bhalla A, Ullman JC, Fang M, Ravi R, Arguello A, Thomsen E, Tsogtbaatar B, Guo JL, Skuja LL, Dugas JC, Davis SS, Poda SB, Gunasekaran K, Costanzo S, Sweeney ZK, Henry AG, Harris JM, Henne KR, Astarita G. High-Throughput Liquid Chromatography-Tandem Mass Spectrometry Quantification of Glycosaminoglycans as Biomarkers of Mucopolysaccharidosis II. Int J Mol Sci 2020;21:E5449. [PMID: 32751752 DOI: 10.3390/ijms21155449] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Poswar FO, Santos HS, Santos ABS, Berger SV, de Souza CFM, Giugliani R, Baldo G. Progression of Cardiovascular Manifestations in Adults and Children With Mucopolysaccharidoses With and Without Enzyme Replacement Therapy. Front Cardiovasc Med 2021;8:801147. [PMID: 35097020 DOI: 10.3389/fcvm.2021.801147] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Hampe CS, Yund BD, Orchard PJ, Lund TC, Wesley J, McIvor RS. Differences in MPS I and MPS II Disease Manifestations. Int J Mol Sci 2021;22:7888. [PMID: 34360653 DOI: 10.3390/ijms22157888] [Reference Citation Analysis]
15 Guffon N, Chowdary P, Teles EL, Hughes D, Hennermann JB, Huot-Marchand P, Faudot-Vernier E, Lacombe O, Fiquet A, Richard MP, Abitbol JL, Tallandier M, Hendriksz CJ. Oral treatment for mucopolysaccharidosis VI: Outcomes of the first phase IIa study with odiparcil. J Inherit Metab Dis 2021. [PMID: 34910312 DOI: 10.1002/jimd.12467] [Reference Citation Analysis]
16 Hoytema van Konijnenburg EMM, Wortmann SB, Koelewijn MJ, Tseng LA, Houben R, Stöckler-Ipsiroglu S, Ferreira CR, van Karnebeek CDM. Treatable inherited metabolic disorders causing intellectual disability: 2021 review and digital app. Orphanet J Rare Dis 2021;16:170. [PMID: 33845862 DOI: 10.1186/s13023-021-01727-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Pierzynowska K, Żabińska M, Gaffke L, Cyske Z, Węgrzyn G. Changes in expression of signal transduction-related genes, and formation of aggregates of GPER1 and OXTR receptors in mucopolysaccharidosis cells. European Journal of Cell Biology 2022;101:151232. [DOI: 10.1016/j.ejcb.2022.151232] [Reference Citation Analysis]
18 Gragnaniello V, Carraro S, Rubert L, Gueraldi D, Cazzorla C, Massa P, Zanconato S, Burlina AB. A new strategy of desensitization in mucopolysaccharidosis type II disease treated with idursulfase therapy: A case report and review of the literature. Molecular Genetics and Metabolism Reports 2022;31:100878. [DOI: 10.1016/j.ymgmr.2022.100878] [Reference Citation Analysis]
19 de Castro MJ, Del Toro M, Giugliani R, Couce ML. Gene Therapy for Neuronopathic Mucopolysaccharidoses: State of the Art. Int J Mol Sci 2021;22:9200. [PMID: 34502108 DOI: 10.3390/ijms22179200] [Reference Citation Analysis]
20 Kong W, Zhang J, Lu C, Ding Y, Meng Y. Glaucoma in mucopolysaccharidoses. Orphanet J Rare Dis 2021;16:312. [PMID: 34266471 DOI: 10.1186/s13023-021-01935-w] [Reference Citation Analysis]
21 Arguello A, Meisner R, Thomsen ER, Nguyen HN, Ravi R, Simms J, Lo I, Speckart J, Holtzman J, Gill TM, Chan D, Cheng Y, Chiu CL, Dugas JC, Fang M, Lopez IA, Solanoy H, Tsogtbaatar B, Zhu Y, Bhalla A, Henne KR, Henry AG, Delucchi A, Costanzo S, Harris JM, Diaz D, Scearce-Levie K, Sanchez PE. Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome. JCI Insight 2021;6:e145445. [PMID: 34622797 DOI: 10.1172/jci.insight.145445] [Reference Citation Analysis]
22 Sampayo-Cordero M, Miguel-Huguet B, Malfettone A, Pérez-García JM, Llombart-Cussac A, Cortés J, Pardo A, Pérez-López J. The Value of Case Reports in Systematic Reviews from Rare Diseases. The Example of Enzyme Replacement Therapy (ERT) in Patients with Mucopolysaccharidosis Type II (MPS-II). Int J Environ Res Public Health 2020;17:E6590. [PMID: 32927819 DOI: 10.3390/ijerph17186590] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Garcia P, Phillips D, Johnson J, Martin K, Randolph LM, Rosenfeld H, Harmatz P. Long-term outcomes of patients with mucopolysaccharidosis VI treated with galsulfase enzyme replacement therapy since infancy. Mol Genet Metab 2021;133:100-8. [PMID: 33775523 DOI: 10.1016/j.ymgme.2021.03.006] [Reference Citation Analysis]
24 Wolfberg J, Chintalapati K, Tomatsu S, Nagao K. Hearing Loss in Mucopolysaccharidoses: Current Knowledge and Future Directions. Diagnostics (Basel) 2020;10:E554. [PMID: 32759694 DOI: 10.3390/diagnostics10080554] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Arguello A, Mahon CS, Calvert ME, Chan D, Dugas JC, Pizzo ME, Thomsen ER, Chau R, Damo LA, Duque J, Fang M, Giese T, Kim DJ, Liang N, Nguyen HN, Solanoy H, Tsogtbaatar B, Ullman JC, Wang J, Dennis MS, Diaz D, Gunasekaran K, Henne KR, Lewcock JW, Sanchez PE, Troyer MD, Harris JM, Scearce-levie K, Shan L, Watts RJ, Thorne RG, Henry AG, Kariolis MS. Molecular architecture determines brain delivery of a transferrin receptor–targeted lysosomal enzyme. Journal of Experimental Medicine 2022;219:e20211057. [DOI: 10.1084/jem.20211057] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]